JP2017519729A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519729A5
JP2017519729A5 JP2016567425A JP2016567425A JP2017519729A5 JP 2017519729 A5 JP2017519729 A5 JP 2017519729A5 JP 2016567425 A JP2016567425 A JP 2016567425A JP 2016567425 A JP2016567425 A JP 2016567425A JP 2017519729 A5 JP2017519729 A5 JP 2017519729A5
Authority
JP
Japan
Prior art keywords
carboxamide
oxabicyclo
heptane
pyridin
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519729A (ja
JP6479051B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030303 external-priority patent/WO2015175487A1/en
Publication of JP2017519729A publication Critical patent/JP2017519729A/ja
Publication of JP2017519729A5 publication Critical patent/JP2017519729A5/ja
Application granted granted Critical
Publication of JP6479051B2 publication Critical patent/JP6479051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567425A 2014-05-13 2015-05-12 軟骨形成を誘導するための化合物および組成物 Active JP6479051B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992815P 2014-05-13 2014-05-13
US61/992,815 2014-05-13
PCT/US2015/030303 WO2015175487A1 (en) 2014-05-13 2015-05-12 Compounds and compositions for inducing chondrogenesis

Publications (3)

Publication Number Publication Date
JP2017519729A JP2017519729A (ja) 2017-07-20
JP2017519729A5 true JP2017519729A5 (enExample) 2018-06-07
JP6479051B2 JP6479051B2 (ja) 2019-03-06

Family

ID=53284520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567425A Active JP6479051B2 (ja) 2014-05-13 2015-05-12 軟骨形成を誘導するための化合物および組成物

Country Status (39)

Country Link
US (6) US9688689B2 (enExample)
EP (2) EP4474384A1 (enExample)
JP (1) JP6479051B2 (enExample)
KR (1) KR102375396B1 (enExample)
CN (1) CN106459076B (enExample)
AP (1) AP2016009502A0 (enExample)
AR (1) AR100418A1 (enExample)
AU (1) AU2015259403B2 (enExample)
BR (1) BR112016025659B1 (enExample)
CA (1) CA2947031C (enExample)
CL (1) CL2016002838A1 (enExample)
CR (1) CR20160528A (enExample)
CU (1) CU24392B1 (enExample)
DK (1) DK3143026T3 (enExample)
EA (1) EA031609B1 (enExample)
ES (1) ES2987439T3 (enExample)
FI (1) FI3143026T3 (enExample)
HR (1) HRP20241236T1 (enExample)
HU (1) HUE067954T2 (enExample)
IL (1) IL248400B (enExample)
JO (1) JO3563B1 (enExample)
LT (1) LT3143026T (enExample)
MA (1) MA39972B1 (enExample)
MX (1) MX377796B (enExample)
MY (1) MY186570A (enExample)
NZ (1) NZ725044A (enExample)
PE (1) PE20161432A1 (enExample)
PH (1) PH12016502005B1 (enExample)
PL (1) PL3143026T3 (enExample)
PT (1) PT3143026T (enExample)
RS (1) RS66122B1 (enExample)
SG (1) SG11201608823RA (enExample)
SI (1) SI3143026T1 (enExample)
SV (1) SV2016005316A (enExample)
TN (1) TN2016000441A1 (enExample)
TW (1) TWI662039B (enExample)
UY (1) UY36118A (enExample)
WO (1) WO2015175487A1 (enExample)
ZA (1) ZA201606929B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1224172A1 (zh) 2013-03-15 2017-08-18 加州生物医学研究所 用於诱导软骨形成的化合物和方法
US9688689B2 (en) * 2014-05-13 2017-06-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
MX2019005621A (es) * 2016-11-14 2019-08-12 Novartis Ag Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.
WO2018200411A1 (en) * 2017-04-24 2018-11-01 The California Institute For Biomedical Research Methods for inducing chondrogenesis
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN111278410A (zh) * 2017-11-10 2020-06-12 诺华股份有限公司 用于关节内应用的延长释放配制品
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
WO2020115683A1 (en) 2018-12-06 2020-06-11 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JP7427665B2 (ja) * 2018-12-06 2024-02-05 ノバルティス アーゲー 関節損傷を治療するための軟骨形成を誘導するための6-ヒドロキシ-8-オキサトリシクロ[3.2.1.02,4]オクタン-2-カルボキサミド誘導体
CN111601789A (zh) * 2018-12-20 2020-08-28 江苏凯迪恩医药科技有限公司 一种含氮杂环化合物、其制备方法及应用
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
RU2733472C1 (ru) * 2020-02-26 2020-10-01 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) N-Ацилгидразон фенхона с фрагментом эпоксиизоиндола, используемый в качестве ингибитора репродукции вируса Хантаан
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2205274B1 (enExample) 1972-11-02 1976-10-01 Sumitomo Chemical Co
US3925554A (en) 1972-11-30 1975-12-09 Sumitomo Chemical Co Certain 3,5-dichlorophenyl compound used as a plant fungicide
US4687865A (en) 1986-06-04 1987-08-18 E. R. Squibb & Sons, Inc. Process for preparing 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
US4707494A (en) 1986-08-26 1987-11-17 E. R. Squibb & Sons, Inc. 7-oxabicyclo(2.2.1)heptane compounds useful in the treatment of inflammation
JP2984077B2 (ja) 1990-04-19 1999-11-29 塩野義製薬株式会社 スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体
US5126370A (en) 1990-12-24 1992-06-30 E. R. Squibb & Sons, Inc. Anti-thrombotic heterocyclic amido prostaglandin analogs
JPH04275182A (ja) 1991-03-01 1992-09-30 Sankyo Kagaku Kk 感熱転写記録用色素
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
HUT74949A (en) 1993-09-10 1997-03-28 Cytomed Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5416106A (en) 1993-12-28 1995-05-16 Allergan, Inc. 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
US6017953A (en) 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
EP0912170A4 (en) 1996-05-02 2003-04-09 Merck & Co Inc HIV PROTEASE INHIBITORS FOR TREATING AIDS
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
MXPA01009073A (es) 1999-03-10 2002-05-06 Phogen Ltd Suministro de acidos nucleicos y proteinas a las celulas.
GB9908021D0 (en) * 1999-04-08 1999-06-02 Lilly Co Eli Pharmaceutical compounds
AU4687500A (en) 1999-04-29 2000-11-17 Allergan Sales, Inc. Thromboxane ligands without blood clotting side effects
JP2003518494A (ja) 1999-12-29 2003-06-10 グラクソ グループ リミテッド アネキシンおよび軟骨ホメオスタシスのモジュレーターに関係する方法と組成物
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CN1213050C (zh) * 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
EP1688412A3 (en) 2001-02-16 2006-08-16 Aventis Pharmaceuticals, Inc. Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BR0307874A (pt) 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
KR20050105511A (ko) 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ep2 선택적 수용체 효능제의 용도
EP1661580B1 (en) 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
JP2005097195A (ja) 2003-09-25 2005-04-14 Institute Of Physical & Chemical Research 医薬組成物
EP1680464A1 (en) 2003-11-07 2006-07-19 Milliken & Company Concentrates of saturated bicyclic dicarboxylate salts as polymer nucleation additives and methods of nucleating thermoplastics
DK2708541T3 (en) 2003-11-13 2015-02-23 Isis Pharmaceuticals Inc 5,6-dihydroxy-isoindole derivatives as linkers for oligomeric solid phase synthesis
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
EP1792622A1 (en) * 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
US7795370B2 (en) 2005-11-15 2010-09-14 Mitsubishi Chemical Corporation Tetracarboxylic acid compound, polyimide thereof, and production method thereof
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US7566797B2 (en) 2006-03-03 2009-07-28 Milliken & Company Metal carboxylate salt nucleating or clarifying agent compounds and related polymer compositions and methods
AU2008214299B2 (en) 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
JP4275182B2 (ja) 2007-11-02 2009-06-10 シャープ株式会社 熱交換器
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
CA2730428A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
EP2318005B1 (en) 2008-08-01 2017-11-01 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
WO2010099573A1 (en) 2009-03-03 2010-09-10 Deakin University Dioxolane norbornane / norbornene compounds suitable as antimicrobial agents to treat bacterial infections
EP2414367B1 (en) * 2009-04-02 2014-08-13 Allergan, Inc. Prostaglandin e receptor antagonists
HRP20130972T1 (hr) 2009-05-18 2013-11-22 Actelion Pharmaceuticals Ltd. Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
CN101628951B (zh) * 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
JP5478161B2 (ja) 2009-09-03 2014-04-23 株式会社クラレ アクリル酸エステル誘導体およびアルコール誘導体並びにそれらの製造方法
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
US8754059B2 (en) 2010-02-16 2014-06-17 University Of Miami Use of miR-30e to treat vascular lesions
WO2011163502A1 (en) 2010-06-24 2011-12-29 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012162535A1 (en) 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
EP2850058B1 (en) 2012-05-16 2016-07-13 Actelion Pharmaceuticals Ltd. 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
WO2014005084A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
CA2876703A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
AU2014292064B2 (en) 2013-07-18 2018-07-05 Idorsia Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
US9688689B2 (en) * 2014-05-13 2017-06-27 Novartis Ag Compounds and compositions for inducing chondrogenesis

Similar Documents

Publication Publication Date Title
JP2017519729A5 (enExample)
HRP20241236T1 (hr) Spojevi i pripravci za induciranje hondrogeneze
US8685993B2 (en) Bi-heteroaryl compounds as Vps34 inhibitors
US7820817B2 (en) Modulators of muscarinic receptors
CA2845578C (en) Pyrimidine pde10 inhibitors
JP6592702B1 (ja) Nav1.7およびNav1.8遮断薬としてのアミド誘導体
JP6175673B2 (ja) Ttx−s遮断薬としてのアミド誘導体
WO2013017461A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
SA520411465B1 (ar) مركبات فعّالة علاجياً وطرق استخدامها
BRPI0720270A2 (pt) Compostos basedos em 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina e processos de usos dos mesmos
EP3661560A1 (en) Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
JP2010508338A5 (enExample)
AR069206A1 (es) Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.
JP2016519096A5 (enExample)
RU2010116352A (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
TW201546070A (zh) 4-氮雜吲哚衍生物
IL205501A (en) Preparation of preparations for the treatment of arthritis
EP3849664A1 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
EP3585365A1 (en) Combination of atr kinase inhibitors with parp inhibitors
WO2020065048A1 (en) Novel compounds as nadph oxidase inhibitors
JP2021521178A (ja) Pi3キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体
TW201216966A (en) Combinations comprising DHODH inhibitors and COX inhibitors
WO2024165470A1 (en) Combinations of dgk (diacylglycerol kinase) inhibitors
JP2022509765A (ja) 関節損傷を治療するための軟骨形成を誘導するための5-ヒドロキシ-7-オキサビシクロ[2.2.1]ヘプタン-2-カルボキサミド誘導体
CN111902404A (zh) 治疗化合物和组合物